世界卫生组织B族链球菌疫苗开发磋商会议:2016年4月27-28日会议报告
全球B族链球菌(GBS)仍是婴儿出生后90天内败血症和脑膜炎的主要病因。许多高收入国家采用产时抗生素预防(IAP)已部分减少GBS疾病负担但未完全消除,而低收入和中等收入国家IAP使用率低。孕妇免疫接种通过胎盘抗体转移及可能减少阴道定植,是保护新生儿和幼婴的替代策略;2016年4月27-28日WHO首次GBS疫苗技术磋商会议讨论了疾病病理生理、全球疾病负担与血清型分布知识缺口、候选疫苗、III期试验设计及许可与政策路径。
要点
- GBS是婴儿出生后90天内败血症和脑膜炎的主要病因,低收入和中等收入国家疾病负担重。
- 许多高收入国家产时抗生素预防已部分减少但未完全消除GBS疾病负担,低收入和中等收入国家使用率低。
- 孕妇免疫接种通过胎盘抗体转移及可能减少阴道定植,是保护新生儿和幼婴的替代策略。
核心结论
- 需要努力解决各领域识别的缺口,以确立对有效GBS疫苗的公共卫生需求、开发和部署。
- 尤其需要更多工作理解GBS相关死胎的全球疾病负担,并开发质量保证的标准化抗体检测以识别保护相关标志。
研究设计与样本
- 2016年4月27-28日WHO首次GBS疫苗技术磋商会议,基于2015年WHO疫苗产品开发咨询委员会会议将GBS列为母体免疫疫苗高优先级。
- 会议讨论主题包括疾病病理生理、全球疾病负担与血清型分布知识缺口、候选疫苗、III期试验设计考虑及许可与政策路径。
主要发现
- 全球GBS仍是婴儿出生后90天内败血症和脑膜炎的主要病因。
- 许多高收入国家产时抗生素预防已部分减少但未完全消除GBS疾病负担,低收入和中等收入国家产时抗生素预防使用率低。
- 孕妇免疫接种策略最早于1970年代提出,几种潜在GBS疫苗已完成I/II期临床试验。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要努力解决各领域识别的缺口,以确立对有效GBS疫苗的公共卫生需求、开发和部署。
- 尤其需要更多工作理解GBS相关死胎的全球疾病负担,并开发质量保证的标准化抗体检测以识别保护相关标志。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Globally, group B Streptococcus (GBS) remains a leading cause of sepsis and meningitis in infants in the first 90days of life. Intrapartum antibiotic prophylaxis (IAP) for women at increased risk of transmitting GBS to their newborns has been effective in reducing part, but not all, of the GBS disease burden in many high income countries (HICs). In low- and middle-income countries (LMICs), IAP use is low. Immunization of pregnant women with a GBS vaccine represents an alternative strategy to protecting newborns and young infants, through transplacental antibody transfer and potentially by reducing new vaginal colonization. This vaccination strategy was first suggested in the 1970s and several potential GBS vaccines have completed phase I/II clinical trials. During the 2015 WHO Product Development for Vaccines Advisory Committee meeting, GBS was identified as a high priority for the development of a vaccine for maternal immunization because of the major public health burden posed by GBS in LMICs, and the high technical feasibility for successful development. Following this meeting, the first WHO technical consultation on GBS vaccines was held on the 27th and 28th of April 2016, to consider development pathways for such vaccines, focused on their potential role in reducing newborn and young infant deaths and possibly stillbirths in LMICs. Discussion topics included: (1) pathophysiology of disease; (2) current gaps in the knowledge of global disease burden and serotype distribution; (3) vaccine candidates under development; (4) design considerations for phase III trials; and (5) pathways to licensure, policy recommendations and use. Efforts to address gaps identified in each of these areas are needed to establish the public health need for, the development and deployment of, efficacious GBS vaccines. In particular, more work is required to understand the global disease burden of GBS-associated stillbirths, and to develop quality-assured standardized antibody assays to identify correlates of protection.
引用
- Kobayashi M, Schrag SJ, Alderson MR, et al. WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27-28 April 2016. Vaccine. 2016. PMID: 28017431. doi:10.1016/j.vaccine.2016.12.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。